Brief: Deciphera Pharmaceuticals Announces FDA Grants Breakthrough Therapy Designation For Qinlock In Second-Line Gist Patients With Mutations In Kit Exon 11 And 17/18

Deciphera Pharmaceuticals

14/03/2023 22:41

March 14 (Reuters) - Deciphera Pharmaceuticals Inc
 DCPH.O :
    * DECIPHERA PHARMACEUTICALS ANNOUNCES QINLOCK® INCLUDED IN
NCCN
GUIDELINES® FOR THE TREATMENT OF SECOND-LINE GIST PATIENTS AND
FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR QINLOCK IN
SECOND-LINE GIST PATIENTS WITH MUTATIONS IN KIT EXON 11 AND
17/18
    * DECIPHERA PHARMACEUTICALS INC - NCCN GUIDELINES INCLUDE
QINLOCK
AS A PREFERRED REGIMEN FOR SECOND-LINE GIST PATIENTS INTOLERANT
TO SUNITINIB
    * DECIPHERA PHARMA- TO START INSIGHT PHASE 3 STUDY OF
QINLOCK
VERSUS SUNITINIB IN SECOND-LINE GIST PATIENTS WITH MUTATIONS IN
KIT EXON 11, 17/18 IN H2 2023

Source text for Eikon:  ID:nBw3l192Va 
Further company coverage:  DCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))